文献速递头颈部肿瘤放疗

头颈癌选择性淋巴结照射60Gy与50Gy的配对分析:疗效与毒性比较

Elective nodal dose of 60 Gy or 50 Gy in head and neck cancers: A matched pair analysis of outcomes and toxicity.
PubMed 文献 · Adv Radiat Oncol · 2017-06-21

该配对分析比较头颈鳞癌调强放疗中选择性淋巴结照射60Gy与50Gy的疗效与毒性。

要点

  • 选择性淋巴结照射50Gy与60Gy的3年局部区域控制率相似,均无选择性照射区孤立区域复发。
  • 50Gy组同侧腮腺平均剂量(35.7Gy vs 42Gy)和甲状腺平均剂量(43.3Gy vs 54.7Gy)显著更低。
  • 50Gy组1年腮腺唾液排泄分数恢复更快,2年生化性甲状腺功能减退发生率更低。

核心结论

  • 50Gy等效剂量足以灭菌未受累淋巴结区域,因孤立区域复发率极低。
  • 选择性淋巴结照射50Gy较60Gy可临床意义上降低头颈鳞癌患者唾液腺与甲状腺毒性。

研究设计与样本

  • 研究为配对分析,纳入两个接受调强放疗且选择性淋巴结照射剂量不同的头颈鳞癌相似队列。
  • 一组接受60Gy(ENI60组),另一组接受50Gy(ENI50组)。
  • 共研究110例患者,基于倾向性评分匹配后97例符合分析条件。

主要发现

  • 两组选择性照射区域均无孤立区域复发。

临床怎么用

  • 对头颈鳞癌未受累淋巴结区域可考虑使用50Gy等效剂量选择性照射以降低唾液腺和甲状腺毒性。
  • 采用50Gy选择性淋巴结照射时需评估局部区域控制情况,因两组控制率相似且无孤立区域复发。

局限性

  • 研究为配对分析,样本量有限(匹配后97例),可能影响结果外推。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The main objective of this study was to evaluate appropriate doses for elective nodal irradiation (ENI) in head and neck squamous cell carcinoma (HNSCC) patients to optimize the therapeutic ratio. METHODS AND MATERIALS: A matched pair analysis of 2 similar cohorts of HNSCC treated with intensity modulated radiation therapy with different dose prescriptions to the elective nodal regions was conducted. One group received 60 Gy, whereas the other received 50 Gy (ENI60 and ENI50 groups, respectively). Isolated regional recurrences (IRR) and locoregional control were evaluated. Doses received by the parotid and thyroid glands were compared among both groups and were clinically correlated with the trend of salivary function recovery and incidence of hypothyroidism. RESULTS: Of the 110 patients studied, 97 were eligible for analysis after matching based on propensity scores. The 3-year locoregional control rate was similar in ENI60 and ENI50 (78.7% and 77%, respectively; P = .93). There were no IRR in ENI regions in either group. The mean ipsilateral parotid dose in ENI60 was significantly higher compared with ENI50 (42 vs 35.7 Gy, P = .03). There was no significant difference in the mean contralateral parotid doses (32.5 vs 31.7 Gy, P = .6). The mean thyroid doses were high in ENI60 compared with ENI50 (54.7 vs 43.3 Gy, P < .001). A significant difference in ipsilateral parotid salivary excretory fraction ratio at 1 year (P = .03) was observed with quicker recovery of salivary function. The salivary excretory fractions were poorer in the ENI60 group with higher mean parotid doses (P = .009). At 2 years, 26 patients (54%) in the ENI60 group and 13 patients (26.5%) in the ENI50 group developed biochemical hypothyroidism (P = .007). CONCLUSIONS: Doses of 50 Gy equivalent are sufficient to sterilize the uninvolved nodal regions because the rates of IRR are extremely low. Using ENI50 results in clinically meaningful reduction in salivary and thyroid toxicity in HNSCC.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Murthy V, Gurram L, Kannan S, et al. Elective nodal dose of 60 Gy or 50 Gy in head and neck cancers: A matched pair analysis of outcomes and toxicity. Adv Radiat Oncol. 2017. PMID: 29114601. doi:10.1016/j.adro.2017.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。